In Reply to Rans et al
- 1 July 2021
- journal article
- editorial
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 110 (3), 911-912
- https://doi.org/10.1016/j.ijrobp.2021.02.040
Abstract
No abstract availableFunding Information
- National Institutes of Health (62880797, P30 CA008748)
- National Cancer Institute (62880797, P30 CA008748)
This publication has 8 references indexed in Scilit:
- In Regard to Zelefsky et alInternational Journal of Radiation Oncology*Biology*Physics, 2021
- Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic CancerInternational Journal of Radiation Oncology*Biology*Physics, 2021
- Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation TrialInternational Journal of Radiation Oncology*Biology*Physics, 2020
- The Multifaceted Role of Chromosomal Instability in Cancer and Its MicroenvironmentCell, 2018
- Predictors of Local Control After Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial MetastasesInternational Journal of Radiation Oncology*Biology*Physics, 2011
- High-Dose, Single-Fraction Image-Guided Intensity-Modulated Radiotherapy for Metastatic Spinal LesionsInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Oligometastases.Journal of Clinical Oncology, 1995